Prospective Study of HPV Specific Immunotherapy in Subjects With HPV Associated Head and Neck Squamous Cell Carcinoma (HNSCCa)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MEDI 0457 (Primary) ; Nivolumab
Indications Head and neck cancer; Human papillomavirus infections; Squamous cell cancer
Focus Adverse reactions
Sponsors Inovio Pharmaceuticals

24 Jan 2019 Results presented in an Inovio Pharmaceuticals media release.
23 Jan 2019 Results from this trial were presented at the Keystone Symposia Conference/Cancer Vaccines being held in Vancouver, Canada by Dr. David B. Weiner, Executive Vice President of The Wistar Institute, Director of its Vaccine Center, and the W. W. Smith Charitable Trust Endowed Professorship in Cancer Research.
02 Oct 2018 Results published in the Inovio Pharmaceuticals Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com